Polyrizon Ltd.

PLRZ

Explore Our Financial Data > Companies > Raanana, Illinois Companies > Polyrizon Ltd.

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker	PLRZ
CIK	0001893645
SIC	2834
Sector	Manufacturing
Industry Category	Pharmaceutical Products
Industry Group	Pharmaceutical Preparations

Contact

Address	12/6 BOROCHOV ST., RAANANA, IL 4343306
Website	polyrizon-biotech.com
Phone	972-54-7979668
CEO	Tomer Izraeli
Employees	N/A

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement

Revenue	$0.00
Pre-Tax Income	$-1.54 million
Net Income	$-1.54 million
Net Income to Common	$-1.54 million
EPS	$0.50

View All

Balance Sheet

Cash	$2.55 million
Assets	$5.55 million
Liabilities	$261,000.00
Common Equity	$5.29 million
Liabilities & Equity	$5.55 million

View All

Cash Flow Statement

Net Income	$-1.54 million
Cash From Operating Activities	$-1.15 million
Cash From Investing Activities	$29,000.00
Cash From Financing Activities	$3.67 million
Change in Cash	$2.55 million

View All

Calculations

NOPAT	$-911,400.00
EBITDA	$-1.18 million
Price to Earnings	N/A
Price to Book	$0.00
ROE	-57.83%

View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Polyrizon Targets $3.15B Epilepsy Market with Preclinical Studies for Innovative Rescue Treatment

Raanana, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, recently announced the initiation of preclinical studies for intranasal Benzodiazepines (BZDs), a first-line treatment for acute repetitive seizures (ARS) and status epilepticus, using its proprietary drug delivery platform. According to the World Health Organization (WHO), epilepsy

Article Link

Top Midday Gainers

Smart Digital Group (SDM) said late Thursday that it priced its initial public offering of 1.5 milli

Article Link

Polyrizon Reports Successful Safety Study of a Formulation of PL-14 Allergy Blocker in Human Nasal Tissue Model

Raanana, Israel, April 25, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product’s development path. Conducted on fully differentiated human nasal tissue using the MucilAir™ model, the study demonstrated strong

Article Link

Polyrizon Receives Nasdaq Notification Regarding Minimum Bid Requirements

Raanana, Israel, April 11, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development stage biotech company specializing in the development of innovative intranasal hydrogels, announced today that on April 8, 2025, the Company received a written notice from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company’s closing bid price for its ordinary shares was below $1.00

Article Link

Polyrizon Engages Leading Branding Firm for Strategic Brand Development

Raanana, Israel, April 02, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ), a biotech company specializing in innovative intranasal hydrogels, today announced that it has entered into an agreement with a globally recognized branding and trademark consultancy firm, renowned for working with leading pharmaceutical and medical device companies worldwide. Under this collaboration, the firm will develop a strategic brand name and identity for Polyrizon’s proprietary Capture and Contain™ (C&C)

Article Link